GSA Capital Partners LLP Trims Holdings in Pulmonx Corporation $LUNG

GSA Capital Partners LLP lessened its holdings in shares of Pulmonx Corporation (NASDAQ:LUNG) by 46.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 403,762 shares of the company’s stock after selling 351,705 shares during the period. GSA Capital Partners LLP owned about 0.98% of Pulmonx worth $892,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of LUNG. Vestal Point Capital LP purchased a new position in Pulmonx during the 3rd quarter valued at about $1,345,000. Bank of America Corp DE increased its holdings in Pulmonx by 556.6% during the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares during the period. Norges Bank bought a new stake in Pulmonx during the 2nd quarter valued at approximately $392,000. Citadel Advisors LLC boosted its position in Pulmonx by 213.5% during the 3rd quarter. Citadel Advisors LLC now owns 217,176 shares of the company’s stock valued at $352,000 after acquiring an additional 147,904 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in Pulmonx by 3,328.7% during the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock valued at $230,000 after acquiring an additional 86,046 shares in the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Performance

Pulmonx stock opened at $1.55 on Friday. The stock’s 50 day simple moving average is $1.36 and its two-hundred day simple moving average is $1.68. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.04 and a current ratio of 4.91. The stock has a market cap of $65.47 million, a price-to-earnings ratio of -1.19 and a beta of 0.18. Pulmonx Corporation has a fifty-two week low of $1.13 and a fifty-two week high of $3.88.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.33) earnings per share for the quarter, meeting the consensus estimate of ($0.33). The business had revenue of $20.59 million for the quarter, compared to analysts’ expectations of $20.43 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. As a group, analysts expect that Pulmonx Corporation will post -1.13 earnings per share for the current fiscal year.

Insider Activity at Pulmonx

In other news, CEO Glendon E. French III sold 67,813 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $1.43, for a total value of $96,972.59. Following the sale, the chief executive officer directly owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. The trade was a 4.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 98,265 shares of company stock valued at $140,519. Insiders own 6.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LUNG. Canaccord Genuity Group cut their price objective on Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research report on Thursday, April 30th. Finally, Wall Street Zen cut Pulmonx from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.58.

Pulmonx Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.